16 September 2021 
EMA/CHMP/508764/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Noxafil 
posaconazole 
On 16 September 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Noxafil. The marketing authorisation holder for this medicinal product is Merck Sharp & Dohme B.V.. 
The CHMP adopted a change to the existing indication for Noxafil gastroresistant tablet and concentrate 
for solution for infusion, to primary treatment of invasive aspergillosis in adults, as follows:2  
Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole 
or in patients who are intolerant of these medicinal products 
For information, the full indications for Noxafil will be as follows: 
Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following 
fungal infections in adults (see section 5.1): 
• 
• 
Invasive aspergillosis; 
Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are 
intolerant of amphotericin B; 
•  Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or 
in patients who are intolerant of itraconazole; 
•  Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or 
fluconazole or in patients who are intolerant of these medicinal products. 
Refractoriness is defined as progression of infection or failure to improve after a minimum of 
7 days of prior therapeutic doses of effective antifungal therapy. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 Removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal 
infections in the following patients: 
• 
Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or 
myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at 
high-risk of developing invasive fungal infections;  
•  Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose 
immunosuppressive therapy for graft versus host disease (GVHD) and who are at high-risk of 
developing invasive fungal infections. 
Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in 
oropharyngeal candidiasis. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
Noxafil  
EMA/CHMP/508764/2021 
Page 2/2 
 
 
 
 
 
